Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

BACKGROUND: The results of phase 1 and phase 2 studies suggest that nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab combined with i...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:N Engl J Med
Hoofdauteurs: Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D., Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier Francesco, Hill, Andrew, Wagstaff, John, Carlino, Matteo S., Haanen, John B., Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A., Ascierto, Paolo A., Long, Georgina V., Callahan, Margaret K., Postow, Michael A., Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M., Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698905/
https://ncbi.nlm.nih.gov/pubmed/26027431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504030
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items